Form 4: Nurix Therapeutics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4) 5 August 2026 6:59 PM

📋All filings for Nurix Therapeutics, INC

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., sold 4,356 shares of common stock on August 5, 2026 for $25.00 per share.

Summary

Option exercise/conversion: acquired 4,356 Common Stock at $1.86 ($8,102) on August 5, 2026; holds 121,583 after (Direct).
Open-market sale: disposed of 4,356 Common Stock at $25.00 ($108,900) on August 5, 2026; holds 117,227 after (Direct).
Option exercise/conversion: disposed of 4,356 Employee Stock Option (right to buy) on August 5, 2026; holds 62,310 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $108,900 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Gwenn Hansen — Officer (Chief Scientific Officer)

Transaction made under a Rule 10b5-1 trading plan.

Date	Transaction	Security	Shares	Price	Value	Held After
2026-08-05	Option exercise/conversion	Common Stock	4,356	$2	$8.1K	121,583
2026-08-05	Open-market sale	Common Stock	4,356	$25	$108.9K	117,227
2026-08-05	Option exercise/conversion	Employee Stock Option (right to buy)	4,356	—	—	62,310

Key Dates

Date	Description
2026-08-05	Option exercise/conversion (4,356 shares)
2026-08-05	Open-market sale (4,356 shares)
2026-08-05	Option exercise/conversion (4,356 shares)

Keywords

insider transaction, Form 4, NRIX, Nurix Therapeutics, Inc., bearish, Gwenn Hansen

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.